David Eisel
YOU?
Author Swipe
View article: Figure S2 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S2 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Expansion of nonvaccine antigen-specific CD8+ T cells in response to RNA-LPX and Alb-IL2 RNA-NP. Number of nonvaccine antigen-specific CD8+ T cells per spleen (gp70 (A), OVA (B)) or per 4 x 106 splenocytes (TRP-1 (C)) 7 days after the last…
View article: Figure S10 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S10 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Representative dot plots corresponding to flow cytometry data displayed in Figure 5.
View article: Figure S7 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S7 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Gating strategy for antigen-specific CD8+ T cells, Tregs, and NK cells displayed in Figure 6.
View article: Figure S11 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S11 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Representative dot plots corresponding to flow cytometry data displayed in Figure 6.
View article: Figure S4 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S4 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Antitumor immunity in response to RNA-LPX and Alb-IL2 RNA-NP. Absolute number of vaccine antigen-specific and nonvaccine antigen-specific CD8+ T cells, Tregs, and NK cells in the tumor (n=6 mice/group; A), tumor-draining lymph node (n=6 mi…
View article: Figure S1 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S1 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Mouse body weight in response to RNA-LPX and Alb-IL2 RNA-NP or rIL-2. Mouse total body weight after each of three weekly i.v. vaccinations with OVA RNA-LPX combined with one (1x) or five (5x) i.p. injections of rIL-2 or one i.v. injection …
View article: Figure S5 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S5 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Gating strategy for antigen-specific CD8+ T cells and Tregs in the blood.
View article: Figure S6 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S6 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Gating strategy for antigen-specific CD8+ T cells in the spleen.
View article: Figure S8 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S8 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Representative dot plots and histograms corresponding to flow cytometry data displayed in Figure 3.
View article: Figure S9 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S9 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Representative dot plots corresponding to flow cytometry data displayed in Figure 4.
View article: Figure S3 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S3 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Expansion of Tregs in response to RNA-LPX and Alb-IL2 RNA-NP. Number of regulatory CD4+ T cells per spleen 7 days after the last of three weekly i.v. vaccinations with gp70 RNA-LPX (A) or OVA RNA-LPX (B) combined with Alb-IL2 RNA-NP or Alb…
View article: Figure S3 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S3 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Expansion of Tregs in response to RNA-LPX and Alb-IL2 RNA-NP. Number of regulatory CD4+ T cells per spleen 7 days after the last of three weekly i.v. vaccinations with gp70 RNA-LPX (A) or OVA RNA-LPX (B) combined with Alb-IL2 RNA-NP or Alb…
View article: Figure S7 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S7 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Gating strategy for antigen-specific CD8+ T cells, Tregs, and NK cells displayed in Figure 6.
View article: Figure S4 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S4 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Antitumor immunity in response to RNA-LPX and Alb-IL2 RNA-NP. Absolute number of vaccine antigen-specific and nonvaccine antigen-specific CD8+ T cells, Tregs, and NK cells in the tumor (n=6 mice/group; A), tumor-draining lymph node (n=6 mi…
View article: Figure S2 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S2 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Expansion of nonvaccine antigen-specific CD8+ T cells in response to RNA-LPX and Alb-IL2 RNA-NP. Number of nonvaccine antigen-specific CD8+ T cells per spleen (gp70 (A), OVA (B)) or per 4 x 106 splenocytes (TRP-1 (C)) 7 days after the last…
View article: Figure S8 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S8 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Representative dot plots and histograms corresponding to flow cytometry data displayed in Figure 3.
View article: Figure S5 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S5 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Gating strategy for antigen-specific CD8+ T cells and Tregs in the blood.
View article: Figure S11 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S11 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Representative dot plots corresponding to flow cytometry data displayed in Figure 6.
View article: Data from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Data from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Interleukin 2 (IL-2) is a crucial cytokine in T-cell immunity, with a promising potential in cancer vaccines. However, therapeutic application of IL-2 is hampered by its short half-life and substantial toxicity. This study reports preclini…
View article: Figure S6 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S6 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Gating strategy for antigen-specific CD8+ T cells in the spleen.
View article: Figure S9 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S9 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Representative dot plots corresponding to flow cytometry data displayed in Figure 4.
View article: Figure S10 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S10 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Representative dot plots corresponding to flow cytometry data displayed in Figure 5.
View article: Figure S1 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Figure S1 from RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity Open
Mouse body weight in response to RNA-LPX and Alb-IL2 RNA-NP or rIL-2. Mouse total body weight after each of three weekly i.v. vaccinations with OVA RNA-LPX combined with one (1x) or five (5x) i.p. injections of rIL-2 or one i.v. injection …
View article: Supplementary Figure 1 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Supplementary Figure 1 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity Open
PDF - 395KB, Supplementary Figure 1: Structure of MO-TES391 and KIAA1864 transcripts.
View article: Supplementary Figure 1 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Supplementary Figure 1 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity Open
PDF - 395KB, Supplementary Figure 1: Structure of MO-TES391 and KIAA1864 transcripts.
View article: Supplementary Figure Legends from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Supplementary Figure Legends from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity Open
PDF - 88KB, Supplementary Figure Legends.
View article: Supplementary Table 3 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Supplementary Table 3 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity Open
PDF - 49KB, Supplementary Table 3: Epitope prediction for HLA-A*02 binding peptides derived from KIAA1864 and MO-TES391.
View article: Supplementary Table 1 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Supplementary Table 1 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity Open
PDF - 60KB, Supplementary Table 1: Serological reactivity of MO-TES391 assessed by SMARTA.
View article: Supplementary Table 1 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Supplementary Table 1 from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity Open
PDF - 60KB, Supplementary Table 1: Serological reactivity of MO-TES391 assessed by SMARTA.
View article: Supplementary Figure Legends from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Supplementary Figure Legends from Alternative Variants of Human <i>HYDIN</i> Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity Open
PDF - 88KB, Supplementary Figure Legends.